PA8849601A1 - Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos - Google Patents
Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismosInfo
- Publication number
- PA8849601A1 PA8849601A1 PA20098849601A PA8849601A PA8849601A1 PA 8849601 A1 PA8849601 A1 PA 8849601A1 PA 20098849601 A PA20098849601 A PA 20098849601A PA 8849601 A PA8849601 A PA 8849601A PA 8849601 A1 PA8849601 A1 PA 8849601A1
- Authority
- PA
- Panama
- Prior art keywords
- monoclonal antibodies
- ferroportina
- same
- count
- reticulocite
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12007608P | 2008-12-05 | 2008-12-05 | |
| US23981809P | 2009-09-04 | 2009-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8849601A1 true PA8849601A1 (es) | 2010-07-27 |
Family
ID=41683589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20098849601A PA8849601A1 (es) | 2008-12-05 | 2009-11-23 | Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP2373335B1 (https=) |
| JP (1) | JP5713917B2 (https=) |
| KR (1) | KR101353117B1 (https=) |
| CN (1) | CN102238962B (https=) |
| AR (1) | AR074398A1 (https=) |
| AU (1) | AU2009322587B2 (https=) |
| BR (1) | BRPI0922288A2 (https=) |
| CA (1) | CA2745618C (https=) |
| CY (1) | CY1117355T1 (https=) |
| DK (1) | DK2373335T3 (https=) |
| EA (1) | EA020472B1 (https=) |
| ES (1) | ES2566343T3 (https=) |
| HR (1) | HRP20160302T1 (https=) |
| HU (1) | HUE028585T2 (https=) |
| IL (1) | IL212731A0 (https=) |
| MX (1) | MX2011005939A (https=) |
| NZ (1) | NZ592545A (https=) |
| PA (1) | PA8849601A1 (https=) |
| PL (1) | PL2373335T3 (https=) |
| SG (1) | SG171960A1 (https=) |
| SI (1) | SI2373335T1 (https=) |
| TW (1) | TW201023891A (https=) |
| UA (1) | UA104741C2 (https=) |
| WO (1) | WO2010065496A1 (https=) |
| ZA (1) | ZA201103941B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014013806A (es) * | 2012-05-14 | 2014-11-26 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
| WO2019213016A1 (en) | 2018-04-30 | 2019-11-07 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| CN110806486B (zh) * | 2019-11-23 | 2023-03-21 | 中南大学湘雅三医院 | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN113980987A (zh) * | 2021-12-06 | 2022-01-28 | 上海市农业科学院 | 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166448B1 (en) | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| IT1319221B1 (it) * | 2000-10-17 | 2003-09-26 | Antonello Pietrangelo | Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria. |
| WO2009094551A1 (en) * | 2008-01-25 | 2009-07-30 | Amgen Inc. | Ferroportin antibodies and methods of use |
-
2009
- 2009-11-23 PA PA20098849601A patent/PA8849601A1/es unknown
- 2009-11-24 AR ARP090104529A patent/AR074398A1/es unknown
- 2009-11-25 TW TW098140185A patent/TW201023891A/zh unknown
- 2009-12-01 HU HUE09760073A patent/HUE028585T2/en unknown
- 2009-12-01 ES ES09760073.8T patent/ES2566343T3/es active Active
- 2009-12-01 CA CA2745618A patent/CA2745618C/en not_active Expired - Fee Related
- 2009-12-01 HR HRP20160302TT patent/HRP20160302T1/hr unknown
- 2009-12-01 EP EP09760073.8A patent/EP2373335B1/en active Active
- 2009-12-01 BR BRPI0922288A patent/BRPI0922288A2/pt not_active IP Right Cessation
- 2009-12-01 DK DK09760073.8T patent/DK2373335T3/en active
- 2009-12-01 KR KR1020117014053A patent/KR101353117B1/ko not_active Expired - Fee Related
- 2009-12-01 PL PL09760073T patent/PL2373335T3/pl unknown
- 2009-12-01 NZ NZ592545A patent/NZ592545A/xx not_active IP Right Cessation
- 2009-12-01 AU AU2009322587A patent/AU2009322587B2/en not_active Ceased
- 2009-12-01 EA EA201170764A patent/EA020472B1/ru not_active IP Right Cessation
- 2009-12-01 JP JP2011539625A patent/JP5713917B2/ja not_active Expired - Fee Related
- 2009-12-01 MX MX2011005939A patent/MX2011005939A/es active IP Right Grant
- 2009-12-01 CN CN200980148354.8A patent/CN102238962B/zh not_active Expired - Fee Related
- 2009-12-01 WO PCT/US2009/066187 patent/WO2010065496A1/en not_active Ceased
- 2009-12-01 SI SI200931382T patent/SI2373335T1/sl unknown
- 2009-12-01 SG SG2011040797A patent/SG171960A1/en unknown
- 2009-12-01 UA UAA201107028A patent/UA104741C2/uk unknown
-
2011
- 2011-05-05 IL IL212731A patent/IL212731A0/en unknown
- 2011-05-27 ZA ZA2011/03941A patent/ZA201103941B/en unknown
-
2016
- 2016-04-12 CY CY20161100296T patent/CY1117355T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201170764A1 (ru) | 2011-12-30 |
| MX2011005939A (es) | 2011-06-27 |
| HUE028585T2 (en) | 2016-12-28 |
| JP5713917B2 (ja) | 2015-05-07 |
| CY1117355T1 (el) | 2017-04-26 |
| EA020472B1 (ru) | 2014-11-28 |
| IL212731A0 (en) | 2011-07-31 |
| AR074398A1 (es) | 2011-01-12 |
| WO2010065496A1 (en) | 2010-06-10 |
| CA2745618A1 (en) | 2010-06-10 |
| BRPI0922288A2 (pt) | 2018-08-28 |
| HK1158977A1 (zh) | 2012-07-27 |
| UA104741C2 (uk) | 2014-03-11 |
| EP2373335B1 (en) | 2016-02-24 |
| SI2373335T1 (sl) | 2016-04-29 |
| PL2373335T3 (pl) | 2016-08-31 |
| JP2012510814A (ja) | 2012-05-17 |
| NZ592545A (en) | 2012-12-21 |
| SG171960A1 (en) | 2011-07-28 |
| TW201023891A (en) | 2010-07-01 |
| KR20110084996A (ko) | 2011-07-26 |
| EP2373335A1 (en) | 2011-10-12 |
| CA2745618C (en) | 2014-06-10 |
| AU2009322587B2 (en) | 2013-09-26 |
| HRP20160302T1 (hr) | 2016-04-22 |
| KR101353117B1 (ko) | 2014-02-17 |
| ES2566343T3 (es) | 2016-04-12 |
| AU2009322587A1 (en) | 2011-07-28 |
| DK2373335T3 (en) | 2016-05-02 |
| ZA201103941B (en) | 2012-11-28 |
| CN102238962B (zh) | 2014-02-12 |
| CN102238962A (zh) | 2011-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8849601A1 (es) | Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos | |
| DOP2020000032A (es) | Proteínas de unión específicas y sus usos | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| AR073717A1 (es) | Anticuerpos anti-notch2 de murino y humano, y metodos de uso | |
| CY1118668T1 (el) | Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων | |
| PH12021550909A1 (en) | Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof | |
| MX2020006715A (es) | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. | |
| MX2019002967A (es) | Anticuerpos de union a cd3. | |
| MX2019005251A (es) | Animales no humanos geneticamente modificados y metodos de uso de los mismos. | |
| CL2007003622A1 (es) | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. | |
| EP2170075A4 (en) | MARKED INHIBITORS OF PROSTATE SPECIFIC MEMBRANEANT (PSMA), BIOLOGICAL ASSESSMENT AND USE AS IMAGING AGENT | |
| EA201390254A1 (ru) | Модифицированные полипептиды релаксина и их применение | |
| ECSP066756A (es) | Anticuerpo monoclonal específico m-csf y los usos del mismo | |
| RU2599417C3 (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| ES2422739T3 (es) | Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB | |
| CO6531481A2 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| EA201070518A1 (ru) | Композиция по уходу за волосами | |
| UA105760C2 (uk) | Антитіло проти bst2 | |
| MX349513B (es) | Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3. | |
| CL2008003190A1 (es) | Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica. | |
| UY32915A (es) | Proteínas de únión específicas y sus usos | |
| AR062268A1 (es) | Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos | |
| BR112017024091A2 (pt) | métodos para o armazenamento de sangue total e composições do mesmo | |
| ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
| CO2020000517A2 (es) | Fragmento fab de anticuerpo anti-ceacam5 de humano novedoso |